High Throughput Platform for the Discovery of GMP Compatible Stem Cell Manufacturing Protocols

用于发现 GMP 兼容干细胞制造协议的高通量平台

• 批准号: 101100
• 金额: $ 93.85万
• 依托单位: PLASTICELL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101100
• 关键词: Throughput; Platform; Discovery; GMP; Compatible

The manufacture of cells in a controlled and reproducible manner is a critical challenge in regenerative medicine. We will develop an integrated platform technology for the rapid identification of novel, efficient stem cell expansion and differentiation protocols that are optimised for translation to clinical grade manufacturing. Several innovative technologies will be combined to perform high throughput GMP compatible screens to discover novel cell production protocols. These protocols will be transferred to a scaled-up bioprocess where a novel cell imaging technology will be utilised to monitor cell performance. Successful protocols will be translated to a GMP manufacturing process for final validation. In this way, safe, robust, cost-effective GMP validated protocols will be rapidly discovered, greatly reducing the cost and time for development of regenerative cell therapeutics.

以受控和可重复的方式制造细胞是再生医学的一个关键挑战。我们将开发一种集成平台技术，用于快速识别新颖、高效的干细胞扩增和分化方案，并针对转化为临床级制造进行优化。将结合多种创新技术来执行高通量 GMP 兼容筛选，以发现新颖的细胞生产方案。这些方案将转移到规模化的生物过程中，其中将利用新型细胞成像技术来监测细胞性能。成功的方案将转化为 GMP 生产流程以进行最终验证。通过这种方式，将快速发现安全、稳健、经济有效的 GMP 验证方案，从而大大降低再生细胞疗法开发的成本和时间。